Bicara Therapeutics (NASDAQ:BCAX) Shares Down 4.5% – Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares fell 4.5% during mid-day trading on Monday . The company traded as low as $25.88 and last traded at $25.88. 142,140 shares were traded during trading, a decline of 76% from the average session volume of 592,123 shares. The stock had previously closed at $27.10.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BCAX. Morgan Stanley lifted their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. The Goldman Sachs Group raised their target price on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Stock Down 0.6%

The company has a market cap of $1.70 billion, a P/E ratio of -9.32 and a beta of -0.75. The business’s 50 day moving average is $25.35 and its 200 day moving average is $21.34.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 28,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the transaction, the chief financial officer owned 129,855 shares in the company, valued at approximately $3,746,316.75. This represents a 17.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total value of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares in the company, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 88,450 shares of company stock worth $2,366,675. 13.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics during the 4th quarter worth $45,000. Legal & General Group Plc raised its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Larson Financial Group LLC boosted its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.